



Adipokines and myokines are important for several biological effects of adipose tissue and skeletal muscle as well as health

NuGO week 2017, Varna, Bulgaria


Christian A. Drevon
 Department of Nutrition,
 Institute of basic medical sciences
 UiO, Norway
c.a.drevon@medisin.uio.no

Public health

- Diet
- Physical activity
- Non-smoking



Myokines & adipokines → health & disease





The adipose organ

Cinti S: The adipose organ, 1999
Editrice Kurtis, Milano Italy

C57BL mouse; 44 % of the adipose organ is anterior (dorsal subcutaneous interscapular +) & ventral (dorsolumbar, inguinal & gluteal)


Most **WAT**

BAT in interscapular, inguinal, mediastinal & perirenal regions




The adipose organ at a glance

Saverio Cinti




Diagrams show the adipose organ of female mice under different conditions. In normal conditions, BAT is present in central regions surrounding the aorta (not shown). Chronic cold (or chronic exercise) causes an increase in the relative amount of BAT throughout the adipose organ, which promotes thermogenesis and has a favorable outcome on metabolism. BAT is 3-4 times more vascularized and innervated than WAT. Pregnancy and lactation induce reversible changes in the size and composition of fat depots to support mammary gland function. In obesity, the size of all fat depots increases, and the relative amount of BAT and adipose organ innervation decreases. Peach regions represent paucilocular adipocytes. Some studies refer to brown adipocytes in WAT as 'brill' adipose tissue, or tissue containing 'beige' adipocytes (see main text for details). Pericardic and omental depots are small and not shown. Scanning EM images from Cinti, 1996, with permission.




Cytology: the adipose organ contains many cell types

Corresponding color in Anatomy panel	Cell type	Markers	Relative size of mitochondria
Red	Adipocytes		
Brown	Brown	UCP1 ⁺ leptin ⁺ S100-B ⁻	Large
Orange	Paucilocular ⁺	UCP1 ^{int} leptin ^{int} S100-B ⁻	Small
Yellow	Small white	UCP1 ⁻ leptin ⁻ S100-B ⁻	Small
Light yellow	Large white	UCP1 ⁻ leptin ⁻ S100-B ⁻	Small
Green	Adipocyte-derived epithelial cell	UCP1 ⁺ leptin ⁺ WAP ⁺	Small
Blue	Immune cells		
Blue	Lymphocyte	Various	Small
Not shown	Macrophage	Various (those in CLS are MAC2 ⁺)	Small

* Paucilocular adipocytes have variable expression of UCP1 and leptin, depending on the stage of differentiation between white and brown adipocytes.



Evidence suggests that adipocyte transdifferentiation might underlie the changes in adipose organ composition that are observed in response to chronic cold or exercise, caloric excess or pregnancy/lactation. De novo adipocyte development is also stimulated by these conditions (see top right panel for details). The factors driving these transdifferentiation pathways are under investigation, but might include those detailed in Box 1 (see main text).



Obesity causes expansion of the adipose organ by increasing the number and size of white adipocytes. On reaching a critical size, white adipocytes are prone to cell death. The obese adipose organ, and particularly visceral fat, is infiltrated with macrophages, which form crown-like structures surrounding dead and dying adipocytes. These macrophages produce pro-inflammatory cytokines that enter the systemic circulation and contribute to the development of insulin resistance. Microscopy image from Cinti et al., 2005, with permission.

Adipose tissue size & location

- Very large 3 - 70 % of body mass
 - May store energy for several months fasting
- Location is important
 - *Subcutaneous*; protect, insulate
 - *Omental*; ectopic, insulin resistance
 - *Perirenal*; protect
 - *Epididymal*; essential fatty acids
 - *Interscapular*; BAT, heat
 - *Inguinal, axillar*; essential fatty acids
 - *Retrobulbar*; support

Adipose tissue (AT) depots

- ~ 85% of total AT is subcutaneous, in lean or obese humans
- The remaining 15% is intra-abdominal, including visceral & retroperitoneal depots
- Visceral AT (mesenteric and omental), only constitutes ~ 10% of total body fat, with the highest risk for metabolic dysregulation




Figure 1. Description of body fat distribution in humans. Lower body: fat storage around the buttocks, hips and thighs. Abdominal subcutaneous: subcutaneous fat storage around the stomach and chest. Overall coverage: fat accumulation in the arms, breast, thighs, buttocks, lower back and breast. Visceral intra-abdominal fat deposition among organs such as the intestines, stomach, liver and pancreas. Fat distributed within the visceral cavity is highly associated with obesity-related health consequences whereas other fat distribution is not.

Metabolic alterations following visceral fat removal and expansion

Foster & Pagliassott. *Adipocyte* 2012, 1, 192-9







Figure 2. Differences between visceral and subcutaneous adipose tissue depots. Drain location: the visceral depot (left) releases products into the portal vein, while the subcutaneous depot (right) releases products into the systemic circulation. In obesity, portal vein effluent to the liver contains higher concentrations of free fatty acids and interleukin-6 compared with the systemic circulation. Adipose depot: Visceral and subcutaneous fat are characterized by inherent differences. When compared with subcutaneous fat, visceral fat is characterized by reduced adiponectin and leptin, increased inflammatory adipocytokines, enhanced lipolysis, a reduced response to insulin and reduced differentiation and angiogenesis.

Adipose tissue functions

- *Storage of*
 - energy - very large & efficient
 - cholesterol, vitamin D & E
- “*Insulation*” - thermic, mechanical & (electrical)
- *Regulation of metabolism* - white & brown
- *Adipokines* – auto-/para-/endocrine

Energy excess





Lipid and lipoprotein metabolism

- lipoprotein lipase
- acylation stimulating protein (ASP)
- prostaglandins, lysophosphatidic acid
- autotaxin (phospholipase D)
- cholesteryl ester transfer protein (CETP)
- retinol binding protein (RBP)

Food intake and SNS activation

- leptin

Vasculature and angiogenesis

- vascular endothelial growth factor (VEGF)
- monobutyrin
- leptin
- FIAF/PGAR/angiopoietin like-4
- angiopoietin-2
- angiotensinogen/angiotensin II.

Metabolism and energy homeostasis

- leptin
- adiponectin
- resistin
- interleukin-6


galanin + receptors

Immune system and acute phase reactants

- tumor necrosis factor- α (TNF- α)
- interleukin-6 and -8 (IL-6 and -8)
- factors C3, B and D of alternate complement system
- monocyte chemoattractant protein (MCP-1)
- α 1-acid glycoprotein
- serum amyloid A3 (SAA3)
- pentraxin 3
- lipocalin 24p3
- metallothionein


Extracellular matrix metabolism

- type VI collagen
- plasminogen activator inhibitor-1 (PAI-1)
- metalloproteases (MMP-2 and MMP-9)
- tissue inhibitors of metalloproteases (TIMP-1 and 2).



Putative batokines and target organs

Villarroya et al. *Nat Rev Endocrinol.* 2017, 13, 26-35




FGF21 and Slit2-C may target WAT browning WAT. FGF21, IL-6 (and ANGPTL8) may improve insulin secretion and β -cell function. NRG4 attenuates hepatic lipogenesis; insulin-like growth factor binding protein 2 (IGFBP2) promotes bone formation; FGF21 and IL-6 may increase cardiac substrate oxidation. BATokines might modulate systemic metabolism indirectly through the CNS; FGF21, IL-6 (and BMP8b) may influence sympathetic activity, feeding, circadian behaviour and female endocrine function. IGF1, insulin-like growth factor 1; NRG4, neuregulin 4.

Leptin expression

- Adipose tissue - white & brown
- Placenta (Hassink et al Pediatrics. 1997; 100 (1):E1)
- Fetus - hair follicles, bone/cartilage (Hoggard et al PNAS. 1997; 94:11073-11078)
- Gastric epithelium (Bado et al Nature. 1998, 394, 790-793)
- Breast gland epithelium (Casabiell et al. J Clin Endocrinol Metab. 1997, 82, 4270-4273)
- Skeletal muscle (Wang et al Nature. 1998, 393, 684-648)
- Bone cells (Reseland et al J Bone & Mineral Res. 2001, 16, 1426-1433)


Expression of leptin & leptin receptor (OB-R) mRNA in human osteoblasts

RT-PCR products



Endocrine effects of leptin on bone metabolism

- ↑ Proliferation
- ↑ Bone mineralization
- ↑ Collagen deposition
- ≈ Leptin
- ≈ Leptin receptor



Bone tissue adapts to the amount of adipose tissue

Gordeladze et al. *J Cell Biochem.* 2002, 85, 825-36

Effect of energy restriction (diet) & physical exercise on mRNA from adipose tissue and whole body MRI

Lee et al. *Phys Report* 2016, 4 (21) e13019

- **Exercise** group used 15,800 kcal/w, increasing to 18,400 kcal during intervention (~17% increase; MyoGlu)
- **Diet** group used 14,500 kcal/w; loss in body weight (75% AT & 25% fat free mass → 2600 kcal/w (18% reduction; NutriTech)

• Thus, similar energy alterations




Table 3. Changes in fat depots after 12 weeks exercise and energy restriction (diet).¹

	Exercise Change (%)	Diet ² Change (%)	Exercise, control Change (%)	Control ² Change (%)
MRI				
Total AT	-10.9 ± 5.1*	-8.9 ± 3.3*	-8.5 ± 2.7*	3.7 ± 1.4
Subcutaneous AT	-7.3 ± 6.0*	-8.6 ± 3.7*	-6.6 ± 2.6*	2.0 ± 1.0
Intra-abdominal AT	-19.4 ± 10.8*	-11.4 ± 6.2*	-16.9 ± 4.2*	7.7 ± 3.3
MRS fat				
Pancreas ³	-28.5 ± 62.9	-20.8 ± 49.7	-30.3 ± 21.7	21.3 ± 20.6
Liver ⁴	-27.4 ± 15.7*	-7.4 ± 2.4*	-23.3 ± 14.1 ⁵	-6.8 ± 1.9*

¹Data represent mean ± SEM. Only relative values are presented due to slight differences in protocols and units calculated in the two cohorts.

²Only data from six subjects in the diet group were available.

³n = 7 in the exercise group.

⁴n = 9 in the exercise group.

⁵The reduction in the control group is significant using the Wilcoxon test (Langley et al. 2016).

*P < 0.05 (baseline vs. 12 weeks).

Table 4. Enrichment analysis of pathways altered in adipose tissue after exercise and energy restriction (diet).¹



	Exercise		Diet	
	Up/down	P-value	Up/down	P-value
Immune-related pathways				
Chemokine signaling pathway	-5.1	2.4E-07	1.7	6.0E-06
Osteoclast differentiation	-5.4	7.5E-08	2.1	2.7E-08
Complement and coagulation cascades	-3.3	6.3E-04	1.3	4.5E-03
Toll-like receptor signaling pathway	-3.8	1.0E-04	1.9	3.0E-03
NOD-like receptor signaling pathway	-2.5	7.4E-03	1.0	6.4E-03
Jak-STAT signaling pathway	-2.3	1.1E-02	1.2	9.2E-03
Hematopoietic cell lineage	-4.1	2.7E-05	2.7	2.1E-12
Natural killer cell mediated cytotoxicity	-5.4	8.3E-08	2.6	6.5E-12
T-cell receptor signaling pathway	-3.4	3.8E-04	1.9	3.1E-07
B-cell receptor signaling pathway	-4.1	3.2E-05	1.3	2.7E-04
Leukocyte transendothelial migration	-4.7	1.8E-06	1.3	2.1E-04
Energy-related pathways				
Glycolysis/gluconeogenesis	0.5	0.040	-8.4	0.014
Citrate cycle (TCA cycle)	0.9	0.002	-1.6	3.7E-05
Fatty acid metabolism	0.9	0.002	-0.9	7.0E-03
Alanine, aspartate and glutamate metabolism	0.5	0.047	-0.8	0.019
Pyruvate metabolism	0.7	0.013	-1.1	0.004
Peroxisome	0.6	0.031	-1.2	9.2E-04
Insulin signaling pathway	0.7	0.011	-0.8	0.014



CAD19

A) Reduced mRNA expression of 12 of 18 markers of adipose tissue M2-like macrophages after exercise

B) Increased mRNA expression of 7 of 18 markers of adipose tissue M1-like macrophages after energy restriction



Energy restriction vs exercise

Lee et al. *Phys Report* 2016, 4 (21) e13019

- Energy restriction
 - **Increased lipolysis**
 - **Increased expression of markers of M1-like macrophages in AT**
 - M1 "killer" macrophages activated by LPS and IFN-g, secrete high amounts of IL-12 & low amounts of IL-10
- Exercise
 - **Reduce expression of markers of M2-like macrophages & T cells**
 - M2 → wound healing & tissue repair; turn off immune activation via anti-inflammatory cytokines like IL-10
 - Resident tissue macrophages can be further elevated by IL-4
 - High levels of IL-10, TGF- β & low levels of IL-12
 - Tumor-associated macrophages are mainly M2, promote tumor growth

Exercise and Regulation of Adipokine and Myokine Production

Prog Mol Biol Transl Sci.
2015, 135, 313-36

Sven W. Görgens^{*}, Kristin Eckardt[†], Jørgen Jensen[‡],
Christian A. Drevon[†], Jürgen Eckel^{*,§,1}





Figure 1 The adipo-myokine concept. A search of original articles in PubMed was performed for the major exercise-regulated myokines and adipokines to identify molecules that were produced and secreted in both tissues. The term adipo-myokines was used for proteins fulfilling both of these criteria. The search terms we used were “skeletal muscle” or “adipose tissue,” “myokine” or “adipokine,” and “exercise.”

Physical activity protects against chronic disorders


- **CVD**; Thompson *ATVB* 2003, **23**, 1319-21
- **Obesity**; Catenacci & Wyatt *Nat Clin Pract Endocrinol. Metab* 2007, **3**, 518-29
- **T2D**; Knowler et al. *NEJM* 2002, **346**, 393-403
- **Osteoporosis**; Gass & Dawson-Hughes *Am J Med* 2006, **119**, S3-11
- **Dementia**; Lautenschlager et al. *JAMA* 2003, **300**, 1027-37
- **Depression**; Martinsen *Acta Psychiatr Scand Suppl* 1994, **377**, 23-7
- **Cancer**; *WCRF report* 2007, colorectal, breast, prostate

Contraction-induced signals like IL-6



**IL-6 from AT
different
skeletal muscle?**

Our strategy for identifying novel myokines



Human grown myotubes in culture; 6 h - FCS

Targeted immunoassay

Proteomic analyses of secretome

LUMINEX multiplex
assay

Concentration by membrane cut-off 3 kD
Separation by 1-D SDS-PAGE
Collection of 10 "bands", Trypsine
MALDI-TOF MS
Data sorting

Hit list including novel myokines

Hit list including ~ 20 most abundant proteins

Validity/ Physiological relevance?

Time-course

Expression detected by RT-PCR & Western


Expression during differentiation of satellite cells to myotubes

Regulated expression/ secretion?

Effect of recombinant peptide in vitro? Paracrine?

Expressed in skeletal muscle tissue?

Expression altered by exercise/ inactivity/ wasting in vivo?



CAD25

Proteomic identification of secreted proteins from human skeletal muscle cells and expression in response to strength training

Norheim et al. *Am J Physiol. Endocrinology & Metabolism*, 2011, 301, E1013-21

- **236 proteins** detected by proteomics in medium from cultured human myotubes
- **18 classically secreted proteins expressed in skeletal muscle**, using the SignalP 3.0 and Human Genome Expression Profile databases together with a published mRNA-based reconstruction of the human skeletal muscle secretome
- **17 of the secreted proteins** exhibited mRNA expression in cultured human myotubes and skeletal muscles biopsies
- **15** of these had significantly **enhanced mRNA expression** in *m. vastus lateralis* and/or *m. trapezius* after 11 wk of strength training

Table 1. "Classically" secreted proteins identified in media conditioned by cultured human muscle cells

Protein Name	QM ^a	Score ^b	MW ^c	Myotubes: mRNA ^d	VL: mRNA ^e
<i>Three Donors</i>					
Secreted protein, acidic and rich in cysteine	28, 16, 11	418, 251, 188	35	3.2502	0.1498
Collagen alpha-1(I) chain	11, 5, 3	214, 74, 50	139	0.5368	0.0022
Lactotransferrin	7, 4, 3	105, 58, 51	78	0.0005	0.0011
Alpha-2-macroglobulin	7, 2, 2	185, 59, 53	163	0.0196	0.0817
Lumican	7, 2, 2	131, 54, 33	38	0.0966	0.0190
Gelsolin	6, 3, 2	212, 48, 68	86	0.3438	0.2232
Cathepsin H	1, 1, 1	71, 65, 50	37	0.0303	0.0045
<i>Two Donors</i>					
Pigment epithelium-derived factor	8, 2	239, 41	46	0.2952	0.1836
Plasminogen activator inhibitor 1	6, 4	149, 155	45	0.7050	0.0006
Cathepsin D	5, 2	171, 39	28	1.2771	0.1332
Tissue inhibitor of metalloproteinase 1	2, 2	117, 63	23	0.6781	0.0127
Fibronectin 1	2, 1	92, 58	262	0.6384	0.0356
Complement C1 s subcomponent	1, 1	69, 45	77	0.1409	0.0452
Cathepsin L1	1, 1	55, 50	38	0.1179	0.0545
<i>One Donor</i>					
Cathepsin B	5	69	38	0.7021	0.0396
Salivary acidic proline-rich phosphoprotein 1/2	5	149	17	0.0001	ND
Follistatin-like 1	3	38	35	0.1642	0.0192
Extracellular matrix protein 1	1	39	61	0.0846	0.0028

^aQM denotes the number matched queries. ^bScore denotes the proteins' MASCOT scores. ^cTheoretical molecular mass of proteins is displayed according to the UniProtKB/ Swiss-Prot entry (mass; kDa). ^dMean mRNA expression from three donors is presented as normalized to RPLP0. ^eMean mRNA expression in m. vastus lateralis biopsies from 10 healthy male subjects normalized to RPLP0


Table 2. Changes in skeletal muscle mRNA levels of secreted muscle proteins in strength-training individuals

Protein Name	M. vastus lateralis	M. trapezius
Collagen alpha-1(I) chain	5.2 (3.7–14.9)*	43.4 (3.9–139.5)*
Secreted protein, acidic and rich in cysteine	2.9 (1.7–4.9)*	9.6 (3.2–18.8)*
Plasminogen activator inhibitor 1	2.6 (1.1–7.8)	4.7 (2.5–18.5)*
Lumican	2.5 (1.7–3.7)*	4.3 (1.1–11.4)*
Tissue inhibitor of metalloproteinase 1	2.1 (1.3–3.6)*	3.0 (1.1–10.3)*
Follistatin-like 1	1.7 (1.2–3.1)*	2.6 (1.0–6.3)*
Fibronectin 1	1.8 (1.4–2.9)*	2.5 (1.2–8.0)
Complement C1 s subcomponent	1.8 (1.0–2.2)*	1.7 (1.2–6.5)
Extracellular matrix protein 1	1.8 (1.0–2.4)*	1.9 (1.4–4.6)*
Alpha-2-macroglobulin	1.8 (0.9–2.2)*	1.9 (1.1–3.0)
Gelsolin	1.5 (0.9–2.1)*	1.7 (1.4–2.9)
Pigment epithelium-derived factor	1.4 (1.1–1.7)	1.8 (1.7–3.0)*
Cathepsin B	1.3 (1.1–1.7)*	1.5 (1.0–2.4)*
Lactotransferrin	1.5 (0.7–2.3)	1.7 (0.8–2.2)
Cathepsin D	1.3 (1.1–1.7)	1.8 (1.1–2.2)*
Cathepsin L1	1.2 (0.8–1.3)	1.5 (1.1–1.8)*
Cathepsin H	1.1 (0.6–1.8)	1.2 (1.0–2.0)

Single exercise bout



Secretion of muscle-derived
adipo-myokines




- ↑ Muscle repair and growth
- ↑ Endothelia function and angiogenesis
- ↑ Adipocyte lipolysis
- ↑ Hepatic glucose release into circulation
- ↓ Inflammation

Chronic exercise training



vs.

Reduction of adipose tissue-derived
pro-inflammatory adipo-myokines




- ↑ Insulin sensitivity
- ↑ Physical fitness
- ↓ Visceral fat mass
- ↓ Inflammation


Plasma concentration of IL-6 (pg/mL)

Langleite et al. *Arch Physiol Biochem.* 2016, 122, 167-79


CONTROLS AT BASELINE




CONTROLS AFTER 12 WEEKS TRAINING



PREDIABETICS AT BASELINE



PREDIABETICS AFTER 12 WEEKS TRAINING



Significant increase in IL-6 after ACUTE exercise (both at 0 and 2 h) $p < 0,01$, but NOT after 12 w training intervention

Extracellular matrix & exercise

Hjorth et al. *Physiol Rep*. 2015 Aug;3(8). pii: e12473

- After 45 min cycling ~ **550** genes were upregulated
 - **28 genes (5%) were directly related to ECM**
- Long-term exercise (12 w) enhanced expression of **289** genes >50%
 - **20% were ECM related**
- > 50% of the proteoglycans in muscle were significantly enhanced after 12 w
- Secretion of the PG serglycin for the first time from SKM
- SRGN KO → enhanced expression & secretion of serpin E1 (SERPINE1; serine proteinase inhibitor superfamily. Inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA) → inhibitor of fibrinolysis)

Belgian blue – mutated gene encoding myostatin
inhibiting muscle growth



Myostatin & exercise in humans

Hjorth et al. *Acta Physiolog*, 2016, 217, 45–60

- Myostatin mRNA expression **reduced** in SKM after acute & long-term PA
- Even further reduced by acute exercise on top of 12 w training
- Expression of myostatin at baseline correlated negatively with insulin sensitivity
- Myostatin expression in AT **increased** after 12 w training
 - **correlated positively with insulin sensitivity markers**
- In cultured SKM cells but not in SGBS cells, myostatin promoted insulin-independent increase of glucose uptake
- SKM cells incubated with myostatin enhanced glucose oxidation & lactate production
- **Myostatin differentially expressed in muscle (-) and AT (+) in relation to PA and dysglycaemia. Recombinant myostatin increased consumption of glucose in human skeletal muscle cells, suggesting a role of myostatin in skeletal muscle glucose metabolism**

Table 2 SignalP-positive genes encoding secretory proteins that were downregulated more than 1.5 times ($FC < 0.667$) in the skeletal muscle during 12 weeks of training ($n = 26$)

Genes	Gene symbol	FPKM*	Fold change [†]	<i>P</i> -value [‡]	<i>q</i> -value [§]
Neuronal pentraxin 1	NPTX1	0.2	0.26	2E-08	3E-07
Cadherin 22, type 2	CDH22	0.2	0.39	3E-07	4E-06
Gremlin 2, DAN family BMP antagonist	GREM2	2.6	0.46	2E-05	1E-04
Protease, serine, 50	PRSS50	1.7	0.53	9E-07	9E-06
Olfactomedin 1	OLFM1	4.6	0.58	1E-11	4E-10
Myostatin	MSTN	3.8	0.58	3E-06	2E-05
Toll-like receptor 9	TLR9	0.6	0.59	4E-13	2E-11
Leucine-rich repeat containing 3B	LRRC3B	4.2	0.62	4E-03	1E-02
CD274 molecule	CD274	2.2	0.63	3E-13	1E-11
Shisa family member 3	SHISA3	0.6	0.63	3E-02	6E-02
LAMB3	LAMB3	2.6	0.64	5E-06	4E-05
Carboxylesterase 1	CES1	0.9	0.65	1E-05	8E-05
Na ⁺ /K ⁺ -transporting ATPase interacting 1	NKAIN1	7.6	0.65	5E-16	4E-14
Rho GDP dissociation inhibitor (GDI) gamma	ARHGDIG	0.7	0.66	2E-02	6E-02
Chondroadherin	CHAD	6.1	0.66	8E-07	9E-06

*Gene expression level at baseline, measured by mRNA sequencing and expressed as fragments per kilobase of transcript per million mapped reads (FPKM).

[†]mRNA expression after 12 weeks of training as compared to baseline of the intervention.


[‡]*P*-value generated in EdgeR.

[§]False discovery rate.

Another strategy is to use whole body intervention to discover new myokines

- Tests before and after training (top)
- Acute 45 min bicycle test at 70% of VO_2max (bottom)
- Blood & muscle samples taken before (B), just after (0'), and 2 h after the acute bout (2 h)
- Subcutaneous adipose tissue biopsies taken 30–60 min after acute exercise

26 middle-aged, sedentary
→ endurance and strength
training for 12 w



Global mRNA sequencing of human skeletal muscle: Search for novel exercise-regulated myokines


Pourteymour et al. *Mol Metab.* 2017, 6, 352-65

- **161** secretory transcripts enhanced (>1.5-fold) after acute exercise & **99** increased after 12 w
- **92** secretory transcripts were reduced after acute and/or long-term physical activity
- Selected **17 unknown** myokines sensitive to short- and/or long-term exercise
- Expression also in cultured human skeletal muscle cells
- One of the 17 candidates was macrophage colony-stimulating factor-1 (CSF1)
- CSF1 mRNA increased in skeletal muscle after acute and long-term exercise, accompanied by a rise in plasma CSF1 protein
- In cultured muscle cells, electrical pulse stimulation (EPS) increased expression and secretion of CSF1
- **Conclusion:** 17 new exercise-responsive myokines. **CSF1** responded to EPS in cultured muscle cells; up-regulated in muscle and plasma after acute & long-term exercise. **Marker of exercise?**


Venn diagrams showing the number of secretory genes that were up- or down-regulated >1.5-fold

Pourteymour et al. *Mol Metab.* 2017, 6, 352-65


Genes up-regulated >1.5 fold









Genes down-regulated >1.5 fold



mRNA expression of selected genes in skeletal muscle biopsies (in A1) or cultured human myotubes. mRNA expression in biopsies was determined with RNAseq (n=26), and in myotubes by RT-PCR (n=5-6)



A) mRNA expression of CSF1 and B) CSF1 receptor (CSF1R) in skeletal muscle biopsies at baseline (A1/A3) and after 12 w (B1eB3), * $p < 0.05$ vs. A1, \$ $p < 0.05$ vs. B1. C) Plasma CSF1 before and after 12 w intervention. D) Differentiating human skeletal muscle cells. E) CSF1 conc in culture medium. Pourteymour et al. *Mol Metab.* 2017, 6, 352-65



C

Major findings after 12 weeks training

Langlete et al. *Arch Physiol Biochem.* 2016, 122, 167-79

- Increased VO_2max ~15 %
- Increased GIR ~30 %
- Dysglycemics reduced body weight (-1.7 kg; $p<0.05$) and waist circumference (-3.7 cm; $p<0.01$)
- Visceral fat preferentially lost compared to other ATdepots
- Hepatic fat was 5-fold higher in dysglycemics than controls, and was reduced after training (29%, $p<0.01$)
- Muscle fat reduced 57% in dysglycemics; 27% in controls
- Change of VO_2max correlated strongly with change of GIR

	Controls		Dysglycemia	
	Baseline	Δ	Baseline	Δ
Age (years)	53 (17)		53 (10)	
Anthropometry				
Height (cm)	185.3 (9.3)		178.6 (5.2)*	
Weight (kg)	73.5 (16.5)	0.7 (2.5)	94.1 (14.1)*	-1.1 (1.9)
BMI (kg/m ²)	23.3 (3.1)	0.2 (0.5)	27.8 (5.3)*	-0.4 (1.2)
Waist circumference (cm) ^a	88 (9)	-0.3 (1.0)	104 (16)*	-3.5 (5.3)* [^]
MRI				
Thigh muscle area (mm ² /kg)	244 (62)	25 (11) [^]	264 (55)	26 (20) [^]
Adipose depots (mL)				
Supraclavicular	78 (37)	-3 (11)	118 (60)*	-3 (19)
Axillary	166 (60)	2 (52)	276 (212)*	-3 (46)
Pericardial	113 (86)	1 (23)	166 (79)	-2 (30)
Subcutaneous	4776 (896)	-340 (548)	8487 (2878)*	-439 (554) [^]
Intraperitoneal	694 (807)	-215 (396) [^]	2236 (984)*	-332 (446) [^] *
Retroperitoneal	851 (621)	-104 (200) [^]	1991 (921)*	-131 (203) [^]
Inguinal	66 (21)	-2 (16)	106 (59)*	-6 (21)
Epididymal	6 (3)	1 (2)	9 (3)*	1 (2)
Popliteal	132 (56)	0 (22)	174 (124)	2 (23)
Aerobic capacity				
VO ₂ max (mL·kg ⁻¹ ·min ⁻¹)	43.4 (6.9)	6.3 (4) [^]	38.7 (8.1)*	4.7 (4) [^]
Maximum strength				
Leg press 1-RM (kg)	188 (58)	25 (20) [^]	250 (33)*	23 (30) [^]
Cable pulldown 1-RM (kg)	70 (18)	10 (9) [^]	75 (18)	10 (10) [^]
Chest press 1-RM (kg)	60 (20)	11 (11) [^]	63 (23)	8 (8) [^]
Blood parameters				
F-B-HbA _{1C} (%) ^b	5.2 (0.8)		5.6 (0.6)*	
F-P-Glucose (mmol/L) ^c	5.3 (1)	0.2 (0.4)	5.8 (0.7)*	0.0 (0.6)
F-S-Insulin (pmol/L)	37.7 (23)	2 (28)	64 (45)*	-0.4 (25)
F-S-C peptide (pmol/L)	568 (129)	63 (273)	944 (351)*	-46 (425)
S-CRP (mg/L)	0.8 (1.5)	0.1 (0.7)	1.6 (2.4)*	0.0 (2.2)

*Different from control group $p < 0.05$.

[^]Pre vs. post within group difference $p < 0.05$.

^aFrom 17 subjects (control $n = 8$, dysglycemic $n = 9$).


^bScreening values (post and Δ are unavailable).

^cNot screening values.

CA

A PGC1- α -dependent myokine that drives brown-fat-like development of white fat and thermogenesis

Boström et al. *Nature*, 2012, 481: 463-8



Francesc Villarroya **Irisin, Turning Up the Heat** *Cell Metabolism* 2012, 15, 277 - 8

Evidence against a beneficial effect of irisin in humans


- Raschke et al. *PlosOne*, 2013, 8(9):e73680
 - Mutation in the start codon ATA in stead of ATG, very little transcription of irisin
- Norheim F et al. *FEBS J.* 2014, 281, 739-4
 - No brownin g of WAT with long-term training
- Albrecht et al. *Sci Rep.* 2015 Mar 9;5:8889
 - All 4 antibodies used in ~ 100 papers are unspecific

Interaction between plasma fetuin-A (hepatokine) and free fatty acids predicts changes in insulin sensitivity in response to long-term exercise

Lee et al. *Physiol Rep.* 2017, Mar;5(5)

- Exercise 12 w reduced plasma fetuin-A conc. ($\sim 11\%$, $P < 0.01$), slightly changed FFAs concentration, and improved glucose infusion rate (GIR) ($\sim 30\%$, $P < 0.01$)
- Changes in plasma fetuin-A & FFAs interacted to predict some of the change in GIR ($b = 42.16$, $P = 0.030$), AT insulin resistance ($b = 0.579$, $P = 0.003$), gene expression of TLR-signaling in AT & AT macrophage mRNA ($b = 94.10$, $P = 0.034$) after exercise
- The relation between FFA levels and insulin sensitivity was specific for fetuin-A in AT
- **Some effect of exercise on insulin sensitivity may be due to changes in plasma hepatokine fetuin-A and FFAs, \rightarrow less TLR4 signaling in AT perhaps by modulating AT macrophages**

Myokines & adipokines → health & disease



Collaborators

Ph Ds/postdocs/researchers

- Ingrid MF Fange
- Kathrine Vinknes
- Helga Refsum
- Thomas Olsen
- Frode Norheim
- Torgrim Langleite
- Anders Kielland
- Marit Hjort
- Torgeir Holen
- Sindre Lee
- Shirin Pourteymour
- Kristin Eckardt
- Yuchuan Li
- Per O. Iversen

External collaborators

- Arild C. Rustan
- Jørgen Jensen
- Kåre I. Birkeland/Hanne L. Gulseth
- Bernd Thiede
- Per K. Hol et al.
- Britt Nakstad, Arild Rønnestad, Ola D. Saugstad,
- Jens P. Berg
- Thomas E. Gundersen, Vitas
- Willem de Vos
- **NuGO** - B van Ommen, H Daniel, M Müller, Robert Caesar
- **Food4Me** - The Gibneys et al
- **NutriTech** - B van Ommen et al
- **MyoGlu** - Birkeland et al.
- **Lifebrain** - Kristine Walhovd/Anders Fjell

Myokines & adipokines – sum up

- Several 100
- Many are important
 - Irisin is not
- Often expressed in many tissues
- Cooperation between many tissues
- *The truth is rarely pure & never simple*
Oscar Wilde
- Thanks for your attention!